https://www.selleckchem.com/pr....oducts/upadacitinib.
Thirteen patients preferred to continue oral medical treatment, while two patients positively approached both STN-DBS and APO. The most common reason patients declined STN-DBS and LCIG was concerned about the surgical operation, while the most common reason APO was declined was its frequent administration of the injection. While STN-DBS was preferred by younger, less severe patients, APO was preferred by older patients who had a longer duration of disease. The most common reason patients declined STN-DBS and LCIG was concerned abou
Like
Comment
Share
